Acrux Signs 10-Year Licensing Deal For Dapsone Gel in Saudi Arabia

MT Newswires Live
2025/07/31

Acrux (ASX:ACR) has signed a 10-year agreement with Servacure Trading to market and distribute its food and drug administration-approved Dapsone 5% Gel in Saudi Arabia, according to a Thursday filing with the Australian bourse.

The product, launched in the US in April 2024 for treating acne vulgaris and available in 60g and 90g packs, will have its regulatory approval and manufacturing managed by Servacure under the agreement, the filing said.

The company will earn a fixed fee per unit shipped monthly, with options to renew the contract after the initial term, the filing added.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10